English

CYCLERION THERAPEUTICS, INC.

EDGAR

CYCN Quarterly report (10-Q) · filed 2026-08-04

Annual consolidated revenue for 2025: about USD 2.074M, using the latest reported figures. The previous period, 2024, was about USD 2M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026-06-30 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-1.43 million USD

2026-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: -2608000 USD Source
Operating Cash Flow: -1176000 USD Source

Free cash flow

-1.43 million USD

2026-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: -2608000 USD Source
Operating Cash Flow: -1176000 USD Source
Capital Expenditure: 66000 USD Source
Capital Expenditure: 66000 USD Source

Cash and cash equivalents: 1.39 million USD 2026-06-30 Source
Exact value

1391000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 4.26 million shares 2026-06-30 Source
Exact value

4256284 shares

Reported share-count change

38.37% · 1.18 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

3075968 shares · 2025-06-30· Source
4256284 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-04.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 4 of 11 periods available· newest 2022-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
liabilities: No compatible figures in this window
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+3.7%

Prior period

USD 2 million

2024-01-01 – 2024-12-31
Current period

USD 2.07 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2074000 − 2000000 = 74000 USD

2000000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2074000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CYCLERION THERAPEUTICS, INC. · 2025-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Year-over-year change in Revenue: 74000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2074000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1200930 Filing: 000119312526132193 Input fundies:Revenue: 2000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1202634 Filing: 000119312526132193
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 471,000

Prior period

−USD 3.06 million

2024-01-01 – 2024-12-31
Current period

−USD 3.53 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-3528000 − -3057000 = -471000 USD

-3057000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-3528000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CYCLERION THERAPEUTICS, INC. · 2025-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Year-over-year change in Net income: -471000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -3528000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1909634 Filing: 000119312526132193 Input fundies:NetIncome: -3057000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1911380 Filing: 000119312526132193
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 1.02 million

Prior period

−USD 4.33 million

2024-01-01 – 2024-12-31
Current period

−USD 3.31 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-3314000 − -4333000 = 1019000 USD

-4333000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-3314000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CYCLERION THERAPEUTICS, INC. · 2025-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Year-over-year change in Operating cash flow: 1019000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -3314000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1514353 Filing: 000119312526132193 Input fundies:OperatingCashFlow: -4333000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1516232 Filing: 000119312526132193
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 2.07 million 100% of revenue
Operating costs Derived USD 7.05 million 340% of revenue
Operating income −USD 4.97 million −240% of revenue
Tax, interest and other Derived −USD 1.45 million −70% of revenue
Net income −USD 3.53 million −170% of revenue

Cash

Operating cash flow −USD 3.31 million −160% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 2,874% of revenue.
2020 Operating loss: operating costs were 3,639% of revenue.
2021 Operating loss: operating costs were 1,500% of revenue.
2022 Operating loss: operating costs were 6,342% of revenue.
2023 Not shown: operating income or net income is not reported.
2024 Operating loss: operating costs were 281% of revenue.
2025 Operating loss: operating costs were 340% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	4507000	129544000 Derived	-125037000	-2029000 Derived	-123008000	-109103000 Derived	Source 2019-01-01 – 2019-12-31: 4507000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -125037000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -123008000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -102215000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 6888000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	2296000	83561000 Derived	-81265000	-3463000 Derived	-77802000	-74014000 Derived	Source 2020-01-01 – 2020-12-31: 2296000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -81265000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -77802000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -72490000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1524000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	3942000	59137000 Derived	-55195000	-3548000 Derived	-51647000	-36524000 Derived	Source 2021-01-01 – 2021-12-31: 3942000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -55195000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -51647000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -36517000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 7000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	297000	18837000 Derived	-18540000	25538000 Derived	-44078000	-40611000 Derived	Source 2022-01-01 – 2022-12-31: 297000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -18540000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -44078000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -40611000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 0 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	12951000 Derived	-12951000	-7688000 Derived	-5263000	Unavailable	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -12951000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -5263000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -21245000 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	2000000	5628000 Derived	-3628000	-571000 Derived	-3057000	Unavailable	Source 2024-01-01 – 2024-12-31: 2000000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -3628000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -3057000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -4333000 USD Inspect Operating Cash Flow Open source
2025 2025-01-01 – 2025-12-31	2074000	7047000 Derived	-4973000	-1445000 Derived	-3528000	Unavailable	Source 2025-01-01 – 2025-12-31: 2074000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -4973000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -3528000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -3314000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.1M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	4507000	Revenue: 4507000 Open source
20202020-12-31	Revenue	2296000	Revenue: 2296000 Open source
20212021-12-31	Revenue	3942000	Revenue: 3942000 Open source
20222022-12-31	Revenue	297000	Revenue: 297000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	2000000	Revenue: 2000000 Open source
20252025-12-31	Revenue	2074000	Revenue: 2074000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

3.7% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 4507000 Open source
20202020-12-31	Year over year	-49.1%	Revenue: 2296000 Open source Revenue: 4507000 Open source
20212021-12-31	Year over year	71.7%	Revenue: 3942000 Open source Revenue: 2296000 Open source
20222022-12-31	Year over year	-92.5%	Revenue: 297000 Open source Revenue: 3942000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 297000 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 2000000 Open source Revenue: 0 Open source
20252025-12-31	Year over year	3.7%	Revenue: 2074000 Open source Revenue: 2000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -239.8% 2025

Net margin -170.1% 2025

Free cash flow margin -13,673.7% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-2,774.3%	Operating Income: -125037000 Open source Revenue: 4507000 Open source
20202020-12-31	Operating margin	-3,539.4%	Operating Income: -81265000 Open source Revenue: 2296000 Open source
20212021-12-31	Operating margin	-1,400.2%	Operating Income: -55195000 Open source Revenue: 3942000 Open source
20222022-12-31	Operating margin	-6,242.4%	Operating Income: -18540000 Open source Revenue: 297000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -12951000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	-181.4%	Operating Income: -3628000 Open source Revenue: 2000000 Open source
20252025-12-31	Operating margin	-239.8%	Operating Income: -4973000 Open source Revenue: 2074000 Open source
20192019-12-31	Net margin	-2,729.3%	Net Income: -123008000 Open source Revenue: 4507000 Open source
20202020-12-31	Net margin	-3,388.6%	Net Income: -77802000 Open source Revenue: 2296000 Open source
20212021-12-31	Net margin	-1,310.2%	Net Income: -51647000 Open source Revenue: 3942000 Open source
20222022-12-31	Net margin	-14,841.1%	Net Income: -44078000 Open source Revenue: 297000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -5263000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	-152.9%	Net Income: -3057000 Open source Revenue: 2000000 Open source
20252025-12-31	Net margin	-170.1%	Net Income: -3528000 Open source Revenue: 2074000 Open source
20192019-12-31	Free cash flow margin	-2,420.7%	Revenue: 4507000 Open source Operating Cash Flow: -102215000 Open source Capital Expenditure: 6888000 Open source
20202020-12-31	Free cash flow margin	-3,223.6%	Revenue: 2296000 Open source Operating Cash Flow: -72490000 Open source Capital Expenditure: 1524000 Open source
20212021-12-31	Free cash flow margin	-926.5%	Revenue: 3942000 Open source Operating Cash Flow: -36517000 Open source Capital Expenditure: 7000 Open source
20222022-12-31	Free cash flow margin	-13,673.7%	Revenue: 297000 Open source Operating Cash Flow: -40611000 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -21245000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 2000000 Open source Operating Cash Flow: -4333000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 2074000 Open source Operating Cash Flow: -3314000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -3.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-102215000	Operating Cash Flow: -102215000 Open source
20202020-12-31	Operating cash flow	-72490000	Operating Cash Flow: -72490000 Open source
20212021-12-31	Operating cash flow	-36517000	Operating Cash Flow: -36517000 Open source
20222022-12-31	Operating cash flow	-40611000	Operating Cash Flow: -40611000 Open source
20232023-12-31	Operating cash flow	-21245000	Operating Cash Flow: -21245000 Open source
20242024-12-31	Operating cash flow	-4333000	Operating Cash Flow: -4333000 Open source
20252025-12-31	Operating cash flow	-3314000	Operating Cash Flow: -3314000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -40.6M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-109103000	Operating Cash Flow: -102215000 Open source Capital Expenditure: 6888000 Open source
20202020-12-31	Free cash flow	-74014000	Operating Cash Flow: -72490000 Open source Capital Expenditure: 1524000 Open source
20212021-12-31	Free cash flow	-36524000	Operating Cash Flow: -36517000 Open source Capital Expenditure: 7000 Open source
20222022-12-31	Free cash flow	-40611000	Operating Cash Flow: -40611000 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -21245000 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -4333000 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -3314000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2019-12-31	Liabilities / assets	Not reported	Total Assets: 186478000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 115378000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 59331000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 18079000 Open source
2023-12-31	Liabilities / assets	Not reported	Total Assets: 13374000 Open source
2024-12-31	Liabilities / assets	Not reported	Total Assets: 9575000 Open source
2025-12-31	Liabilities / assets	Not reported	Total Assets: 9985000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.15× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	5.55×	Current Assets: 101197000 Open source Current Liabilities: 18249000 Open source
20202020-12-31	Current assets / current liabilities	3.45×	Current Assets: 58501000 Open source Current Liabilities: 16952000 Open source
20212021-12-31	Current assets / current liabilities	5×	Current Assets: 55457000 Open source Current Liabilities: 11085000 Open source
20222022-12-31	Current assets / current liabilities	1.94×	Current Assets: 14820000 Open source Current Liabilities: 7627000 Open source
20232023-12-31	Current assets / current liabilities	3.85×	Current Assets: 8024000 Open source Current Liabilities: 2086000 Open source
20242024-12-31	Current assets / current liabilities	5.83×	Current Assets: 4225000 Open source Current Liabilities: 725000 Open source
20252025-12-31	Current assets / current liabilities	5.15×	Current Assets: 4635000 Open source Current Liabilities: 900000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 123.01 million Exact value Exact value: -123008000 USD 2019-01-01 – 2019-12-31: -123008000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYCLERION THERAPEUTICS, INC. · 2019-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Net Income: -123008000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -123008000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000156459021008434/cycn-20201231.xml#109129 Filing: 000156459021008434 The citation records this snapshot. The page link may show a newer release later.	−USD 102.22 million Exact value Exact value: -102215000 USD 2019-01-01 – 2019-12-31: -102215000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYCLERION THERAPEUTICS, INC. · 2019-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Operating Cash Flow: -102215000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -102215000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000156459021008434/cycn-20201231.xml#128941 Filing: 000156459021008434 The citation records this snapshot. The page link may show a newer release later.	USD 6.89 million Exact value Exact value: 6888000 USD 2019-01-01 – 2019-12-31: 6888000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYCLERION THERAPEUTICS, INC. · 2019-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Capital Expenditure: 6888000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6888000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000156459021008434/cycn-20201231.xml#129364 Filing: 000156459021008434 The citation records this snapshot. The page link may show a newer release later.	−USD 109.1 million Calculation and evidence -102215000 − 6888000 USD Exact free cash flow: -109103000 USD 2019-01-01 – 2019-12-31: -102215000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 6888000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYCLERION THERAPEUTICS, INC. · 2019-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Free cash flow: -109103000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -102215000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000156459021008434/cycn-20201231.xml#128941 Filing: 000156459021008434 Input fundies:CapitalExpenditure: 6888000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000156459021008434/cycn-20201231.xml#129364 Filing: 000156459021008434 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 77.8 million Exact value Exact value: -77802000 USD 2020-01-01 – 2020-12-31: -77802000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYCLERION THERAPEUTICS, INC. · 2020-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Net Income: -77802000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -77802000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017022001958/cycn-20211231.htm#2274775 Filing: 000095017022001958 The citation records this snapshot. The page link may show a newer release later.	−USD 72.49 million Exact value Exact value: -72490000 USD 2020-01-01 – 2020-12-31: -72490000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYCLERION THERAPEUTICS, INC. · 2020-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Operating Cash Flow: -72490000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -72490000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017022001958/cycn-20211231.htm#1562902 Filing: 000095017022001958 The citation records this snapshot. The page link may show a newer release later.	USD 1.52 million Exact value Exact value: 1524000 USD 2020-01-01 – 2020-12-31: 1524000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYCLERION THERAPEUTICS, INC. · 2020-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Capital Expenditure: 1524000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1524000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017022001958/cycn-20211231.htm#1570015 Filing: 000095017022001958 The citation records this snapshot. The page link may show a newer release later.	−USD 74.01 million Calculation and evidence -72490000 − 1524000 USD Exact free cash flow: -74014000 USD 2020-01-01 – 2020-12-31: -72490000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1524000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYCLERION THERAPEUTICS, INC. · 2020-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Free cash flow: -74014000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -72490000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017022001958/cycn-20211231.htm#1562902 Filing: 000095017022001958 Input fundies:CapitalExpenditure: 1524000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017022001958/cycn-20211231.htm#1570015 Filing: 000095017022001958 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 51.65 million Exact value Exact value: -51647000 USD 2021-01-01 – 2021-12-31: -51647000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYCLERION THERAPEUTICS, INC. · 2021-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Net Income: -51647000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51647000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009223/cycn-20221231.htm#2326271 Filing: 000095017023009223 The citation records this snapshot. The page link may show a newer release later.	−USD 36.52 million Exact value Exact value: -36517000 USD 2021-01-01 – 2021-12-31: -36517000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYCLERION THERAPEUTICS, INC. · 2021-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Operating Cash Flow: -36517000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36517000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009223/cycn-20221231.htm#1628815 Filing: 000095017023009223 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2021-01-01 – 2021-12-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYCLERION THERAPEUTICS, INC. · 2021-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009223/cycn-20221231.htm#1636466 Filing: 000095017023009223 The citation records this snapshot. The page link may show a newer release later.	−USD 36.52 million Calculation and evidence -36517000 − 7000 USD Exact free cash flow: -36524000 USD 2021-01-01 – 2021-12-31: -36517000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYCLERION THERAPEUTICS, INC. · 2021-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Free cash flow: -36524000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36517000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009223/cycn-20221231.htm#1628815 Filing: 000095017023009223 Input fundies:CapitalExpenditure: 7000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009223/cycn-20221231.htm#1636466 Filing: 000095017023009223 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 44.08 million Exact value Exact value: -44078000 USD 2022-01-01 – 2022-12-31: -44078000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYCLERION THERAPEUTICS, INC. · 2022-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Net Income: -44078000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44078000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017024025935/cycn-20231231.htm#1841261 Filing: 000095017024025935 The citation records this snapshot. The page link may show a newer release later.	−USD 40.61 million Exact value Exact value: -40611000 USD 2022-01-01 – 2022-12-31: -40611000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYCLERION THERAPEUTICS, INC. · 2022-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Operating Cash Flow: -40611000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40611000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017024025935/cycn-20231231.htm#1280959 Filing: 000095017024025935 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2022-01-01 – 2022-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYCLERION THERAPEUTICS, INC. · 2022-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009223/cycn-20221231.htm#1634349 Filing: 000095017023009223 The citation records this snapshot. The page link may show a newer release later.	−USD 40.61 million Calculation and evidence -40611000 − 0 USD Exact free cash flow: -40611000 USD 2022-01-01 – 2022-12-31: -40611000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYCLERION THERAPEUTICS, INC. · 2022-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Free cash flow: -40611000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40611000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017024025935/cycn-20231231.htm#1280959 Filing: 000095017024025935 Input fundies:CapitalExpenditure: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009223/cycn-20221231.htm#1634349 Filing: 000095017023009223 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 5.26 million Exact value Exact value: -5263000 USD 2023-01-01 – 2023-12-31: -5263000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYCLERION THERAPEUTICS, INC. · 2023-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Net Income: -5263000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5263000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312525277621/cycn-20241231.htm#1382591 Filing: 000119312525277621 The citation records this snapshot. The page link may show a newer release later.	−USD 21.25 million Exact value Exact value: -21245000 USD 2023-01-01 – 2023-12-31: -21245000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYCLERION THERAPEUTICS, INC. · 2023-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Operating Cash Flow: -21245000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21245000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312525277621/cycn-20241231.htm#780123 Filing: 000119312525277621 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 3.06 million Exact value Exact value: -3057000 USD 2024-01-01 – 2024-12-31: -3057000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYCLERION THERAPEUTICS, INC. · 2024-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Net Income: -3057000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3057000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1911380 Filing: 000119312526132193 The citation records this snapshot. The page link may show a newer release later.	−USD 4.33 million Exact value Exact value: -4333000 USD 2024-01-01 – 2024-12-31: -4333000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYCLERION THERAPEUTICS, INC. · 2024-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Operating Cash Flow: -4333000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4333000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1516232 Filing: 000119312526132193 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 3.53 million Exact value Exact value: -3528000 USD 2025-01-01 – 2025-12-31: -3528000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYCLERION THERAPEUTICS, INC. · 2025-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Net Income: -3528000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3528000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1909634 Filing: 000119312526132193 The citation records this snapshot. The page link may show a newer release later.	−USD 3.31 million Exact value Exact value: -3314000 USD 2025-01-01 – 2025-12-31: -3314000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYCLERION THERAPEUTICS, INC. · 2025-12-31 CYCLERION THERAPEUTICS, INC. (edgar:1755237) Operating Cash Flow: -3314000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1755237/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3314000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-20251231.htm#1514353 Filing: 000119312526132193 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

44 filings · 1,811 latest values · 1,811 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001755237, 1755237, CYCN, KRSA, cycn, edgar:1755237

Also known as CYCLERION THERAPEUTICS, INC., CYCLERION THERAPEUTICS, INC., Cyclerion Therapeutics, Inc., Korsana Biosciences, Inc.

CYCLERION THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation